Dangprasert S, Pochanugool L, Likitkitchphysain B
Department of Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Med Assoc Thai. 1998 Sep;81(9):728-32.
Osteosarcoma is a fatal disease. Neoadjuvant chemotherapy combined with irradiation treatment provide a better survival. In the Faculty of Medicine, Ramathibodi Hospital, the overall 9 year survival probability was 55 per cent among 130 cases of more than Enneking stage II osteosarcoma. Between 15 cases of bony metastases, there were 2 cases which were classified as multifoci osteosarcoma or osteosarcomatosis. These two cases developed second bone disease, 32 and 38 months after initial diagnosis and survived for 84 and 88 months with one patient also developing pulmonary metastasis. Both of them are still alive and in very good health.
骨肉瘤是一种致命疾病。新辅助化疗联合放射治疗可提高生存率。在拉玛蒂博迪医院医学院,130例Enneking分期超过II期的骨肉瘤患者的9年总生存率为55%。在15例骨转移患者中,有2例被归类为多灶性骨肉瘤或骨肉瘤病。这两例患者在初次诊断后32个月和38个月出现了第二种骨病,分别存活了84个月和88个月,其中1例还出现了肺转移。两人仍在世且健康状况良好。